As brands grow their digital footprint across many message delivery channels; we often see them temporarily alter brand colors, shapes and other elements to celebrate a holiday, recognize a social cause, or commemorate an industry-specific event to build awareness. Some may see this practice as distracting, off-message or empty posturing. Others determine it a necessary disruption to bring attention to various topics, regardless of how it relates back to the company. Both viewpoints are valid, and with the practice increasing in popularity, it is worth discussion.

What do they mean for you?

Capacity: The total amount that can be contained or produced
Capability: The ability to do something
*As defined by the Cambridge Dictionary

One of the issues I’ve heard raised in our industry is about how we define capacity and capability. As you can see from the definitions above, these are two very different items. But what do these two terms mean with respect to the manufacture of mRNA drug substance and/or drug product?

A new means to fight stem cell transplant infections

When attending a large event such as Advanced Therapies Week, you are able to reach outside your regular workspace and learn about numerous developments happening in other spaces. One in particular that I learned of is an exciting advance in a new ex vivo cell therapy from Smart Immune. It's designed to help those who receive allogenic bone marrow transplants as part of treatment for cancer, such as leukemia, lymphoma, or myeloma, which can leave a patient in an immunosuppressive state.

Meet a new catalog CRISPR protein

If you were at the Advanced Therapies Week in Miami from January 17-20, you learned first-hand about our newest catalog CRISPR protein, Eureca-V™ Nuclease. But what exactly is Eureca-V? In short, the core technology for Eureca-V is the proprietary MAD7® nuclease developed by Inscripta®. Aldevron and Inscripta have partnered to make this protein broadly available to the therapeutic, diagnostic, and agricultural research markets.